[Therapy for hormone-refractory prostate cancer].
Nishimura
Kazuo
K
Department of Urology, Graduate School of Medicine, Osaka University.
Takahara
Shiro
S
Nonomura
Norio
N
Okuyama
Akihiko
A
D000728:Androgens; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D002986:Clinical Trials as Topic; D004002:Clodronic Acid / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D000077143:Docetaxel; D004961:Estramustine / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D013326:Strontium Radioisotopes / Q000627:therapeutic use; D043823:Taxoids; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
D000728:Androgens; D013326:Strontium Radioisotopes; D043823:Taxoids; D004002:Clodronic Acid; D005641:Tegafur; D000077143:Docetaxel; D004961:Estramustine; D003907:Dexamethasone; D003520:Cyclophosphamide; D017239:Paclitaxel